412 filings
Page 5 of 21
8-K
jtndp0dk
9 Jan 23
Departure of Directors or Certain Officers
7:27am
8-K
xr9yhemlh4bsws
29 Nov 22
Departure of Directors or Certain Officers
7:53am
8-K
uh27sq
18 Nov 22
Other Events
8:17am
8-K
oghr35a
9 Nov 22
KemPharm Reports Third Quarter 2022 Results
4:24pm
8-K
r8yq2834h px2yarg
11 Aug 22
KemPharm Reports Second Quarter 2022 Financial Results and Corporate Updates
4:25pm
8-K
00wiu
1 Jul 22
Submission of Matters to a Vote of Security Holders
8:32am
DEFA14A
licyuouxua3jzsojiec
17 Jun 22
Additional proxy soliciting materials
9:17am
8-K
28i2suf7o2y
17 Jun 22
Changes in Registrant's Certifying Accountant
9:14am
8-K
4fzpw z9dte3yd
31 May 22
Entry into a Material Definitive Agreement
9:13pm
8-K
e7s5 uj7o
16 May 22
KemPharm Announces Strategic Acquisition of Arimoclomol from Orphazyme, Expanding its Rare CNS Diseases Pipeline
8:40am
DEFA14A
8us jfuq9
12 May 22
Additional proxy soliciting materials
5:26pm
8-K
okuzwyuz5yak8a
12 May 22
KemPharm Reports First Quarter 2022 Financial Results and Corporate Updates
4:48pm
8-K
8xwyl
30 Mar 22
KemPharm Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Corporate Updates
4:36pm
8-K
9bo24d21
21 Mar 22
KemPharm Announces Full Data Set from Higher-Dose Serdexmethylphenidate (SDX) Phase 1 Clinical Trial
8:49am
8-K
z1628vfg
16 Mar 22
KemPharm team provided development and regulatory services to Corium pursuant to a master development services agreement
8:32am